The Application of Ketamine for Sedation in Patients With Cardiac Arrest - - KetCat (KETamine in Cardiac ArresT) Study

Not Applicable

Recruiting

• Conditions: Cardiac Arrest, Out-Of-Hospital; Neurologic Manifestations; Ketamine
• Interventions: Drug: Ketamine Hydrochloride

• Registration Number: NCT04360070
• Lead Sponsor: Fraser Health

Brief Summary

Recent evidence suggests ketamine may attenuate harmful cellular cascades taking place after brain injury that result in permanent damage. The investigators are interested in researching the application of this in the setting of cardiac arrest. Following cardiac arrest, the brain is deprived oxygen for a period of time, leading to the imitation of these harmful cellular processes. The investigators hypothesize that patients who receive ketamine as part of their standard sedation procedures during cardiac arrest treatment have better neurological functioning compared to those who do not.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-04-21
• Study First Submitted QC: 2020-04-22
• Study First Posted: 2020-04-24
• Study Start: 2022-02-28
• Status Verified: 2023-01
• Last Update Submitted: 2023-01-06
• Last Update Posted: 2023-01-10
• Primary Completion: 2023-12-09
• Study Completion: 2023-12-12

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

• All out-of-hospital cardiac arrests (OHCA) with a "shockable rhythm" (ventricular fibrillation, pulseless ventricular tachycardia) that present to the Royal Columbian Hospital. The patient may be either in active cardiac arrest with shockable rhythm or may have achieved Return of Spontaneous Circulation (ROSC).
• Over 19 years of age
• Patients requiring sedation based on the assessment of the resuscitating physician.

Exclusion Criteria

• Any other type of cardiac arrest
• Any history of previous, pre-existing neurological deficit
• Started on Extracorporeal Membrane Oxygenation (ECMO)
• Duration of cardiac arrest without ROSC is greater than 30 consecutive minutes
• Known contraindication or hypersensitivity to ketamine
• Awake patient or no standard sedation or no intubation required
• Inability to obtain deferred consent
• Currently enrolled in any other research study involving drugs or devices
• Patients who are pregnant
• Patients who are prisoners
• Patients residing in Long Term Care (LTC) facilities

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Ketamine Arm	Ketamine Hydrochloride	Patients randomized to the ketamine arm will receive ketamine as part of their sedation medications during their cardiac arrest treatment

Primary Outcome Measures

Name	Time	Method
Feasibility Data	through study completion, an average of 6 months.	To test the appropriateness of the eligibility criteria by recording enrolment rates of eligible patients, test the randomization assignment procedures by evaluating for any difference in baseline characteristics between groups, and test adequate adherence to protocol by recording time taken to administer intervention during sedation procedures.

Trial Locations

Locations (1)

Fraser Health Authority - Royal Columbian Hospital; 🇨🇦 New Westminster, British Columbia, Canada